Nxera Pharma Co., Ltd. Logo

Nxera Pharma Co., Ltd.

Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.

4565 | T

Overview

Corporate Details

ISIN(s):
JP3431300007
LEI:
Country:
Japan
Address:
港区赤坂9−7−2
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nxera Pharma Co., Ltd. (formerly Sosei Group) is a technology-driven biopharmaceutical company focused on the discovery and development of specialty medicines. Its mission is to accelerate the creation of life-changing treatments for patients with unmet medical needs, both in Japan and globally. The company leverages its proprietary structure-based drug design (SBDD) platform and drug development capabilities to advance a diverse pipeline of therapeutic programs. Nxera Pharma actively seeks partnerships to pursue breakthrough discoveries and bring innovative medicines to market, with a focus on areas such as neurology and gastroenterology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 09:06
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 09:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 41.8 KB
2025-08-08 08:57
Report Publication Announcement
確認書
Japanese 8.4 KB
2025-08-08 08:55
Interim Report
半期報告書-第36期(2025/01/01-2025/12/31)
Japanese 287.5 KB
2025-04-16 08:57
Registration Form
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:55
Registration Form
訂正有価証券届出書(参照方式)
Japanese 41.6 KB
2025-04-16 08:53
Registration Form
訂正有価証券届出書(参照方式)
Japanese 39.8 KB
2025-04-16 08:51
Remuneration Information
臨時報告書
Japanese 32.4 KB
2025-03-26 08:42
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:41
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 42.2 KB
2025-03-26 08:40
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 40.4 KB
2025-03-26 08:38
Regulatory News Service
臨時報告書
Japanese 28.0 KB
2025-03-26 08:37
Regulatory News Service
内部統制報告書-第35期(2024/01/01-2024/12/31)
Japanese 23.8 KB
2025-03-26 08:36
Regulatory News Service
確認書
Japanese 8.6 KB
2025-03-26 08:35
Annual Report
有価証券報告書-第35期(2024/01/01-2024/12/31)
Japanese 1.3 MB

Automate Your Workflow. Get a real-time feed of all Nxera Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nxera Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nxera Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.